News

Promising Findings on Pedmark: Enhancing Treatment for Cancer

Promising Findings on Pedmark: Enhancing Treatment for Cancer

Promising Results from the Pedmark Study

Fennec Pharmaceuticals Inc. (NASDAQ: FENC) has shared exciting topline results from a crucial study on Pedmark, a sodium thiosulfate injection. This trial focused on reducing cisplatin-induced ototoxicity in pediatric and young adult patients with non-metastatic solid tumors. The study was conducted in Japan and has shown significant positive outcomes.

Pedmark's Unique Position in Cancer Treatment

Pedmark stands out as the only FDA-approved therapy designed to lower the risk of hearing loss associated with cisplatin treatment in children aged one month and older with localized tumors. Cisplatin and similar chemotherapy drugs are integral in treating a variety of solid tumors, making the quest for effective supportive therapies essential.

Study Details and Performance

The study involved 27 patients aged between 3 and 18 years in the main cohort, alongside six patients in exploratory cohorts. The administration of Pedmark occurred six hours post-cisplatin treatment, aiming to mitigate potential hearing loss.

Key Findings: Reduced Hearing Loss Rates

Encouragingly, the primary endpoint of the study was achieved. The results revealed that 24% of evaluable patients treated with Pedmark experienced hearing loss, as measured by American Speech-Language-Hearing Association criteria, and 16% based on Brock grading. These figures are notably lower than the historical averages seen in previous pivotal trials of Pedmark, where 56% of children faced clinically significant hearing loss.

Subgroup Analysis

Diving deeper, the analysis of the largest subgroup comprising patients aged 7-18 years showed even better outcomes, with only 19% experiencing hearing loss under ASHA criteria, and just 14.3% under the Brock grading system. These outcomes underscore the potential of Pedmark in minimizing the risks commonly associated with cisplatin treatment.

Safety and Efficacy of Pedmark

Pharmacokinetic evaluations indicated that pedmark did not diminish the effectiveness of cisplatin nor was there any adverse interaction noted. In fact, the overall tumor response rate remained impressively high at around 95%, confirming that Pedmark maintains its antitumor activity without compromising patient safety.

Importantly, Pedmark was well-tolerated throughout the trial, with over 200 reported adverse events where none were linked to the therapy itself. This safety profile bolsters confidence in Pedmark as a supportive treatment during chemotherapy.

Future Plans for Pedmark

Fennec Pharmaceuticals is keen on continuing its positive trajectory with Pedmark. The company plans to pursue regulatory registration in Japan and explore potential partnerships or licensing arrangements to broaden the accessibility of this innovative therapy. Full details of the study will be unveiled in upcoming scientific presentations and submitted for publication in peer-reviewed journals.

FENC Stock Performance

In market activity, shares of Fennec Pharmaceuticals saw a slight decline of 0.78%, settling at $7.85 on the publication date. Investors remain hopeful as the results from this study have the potential to enhance the value of the company's offering in the oncology market.

Frequently Asked Questions

What does Pedmark do?

Pedmark is a sodium thiosulfate injection approved by the FDA to reduce the risk of hearing loss caused by cisplatin chemotherapy in pediatric patients.

What were the findings of the recent study on Pedmark?

The study demonstrated that only 24% of participants treated with Pedmark experienced hearing loss, which is significantly lower than historical rates.

Is Pedmark safe for children?

Yes, the study found that Pedmark was well-tolerated, with no adverse effects linked to the drug during the trial.

What are Fennec Pharmaceuticals' future plans for Pedmark?

Fennec plans to pursue regulatory registration in Japan and seek partnership opportunities to expand the availability of Pedmark.

How did Fennec Pharmaceuticals' stock perform following the study announcement?

Fennec Pharmaceuticals' shares declined by 0.78%, trading at $7.85 at the time of the announcement, reflecting investors' cautious optimism in response to the study results.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

U.S. Employers Signal a Deeper Multilingual Skills Gap

Updated Category News Views 125

A language gap rarely makes the loudest noise in an earnings call, yet it can quietly wreck a sales effort, a hiring plan, or a customer relationship. ACTFL's updated 2026 employer study puts some hard edges around that problem: U.S. businesses say multilingual capability is not a nice cultural accessory. It is increasingly part of operating the business. Demand Has Moved...

Continue Reading
Travel Disruptions Reveal the Value of Human Support

Updated Category News Views 119

Air travel’s ugly little secret surfaced again during the recent ground stop: a reservation is easy, but rescuing a trip is labor-intensive, fast-moving work. Internova Travel Group says its people across Travel Leaders Network, Global Travel Collection and ALTOUR moved quickly as cancellations piled up and travelers were left staring at busted itineraries. That is not...

Continue Reading
S&P Global's UBS AI Conference Slot Deserves Attention

Updated Category News Views 109

Thirty Minutes Can Still Matter A half-hour fireside chat is not a quarterly earnings call, and anybody treating it like one is setting themselves up for disappointment. Still, S&P Global CEO Martina Cheung appearing at the UBS Global Technology and AI Conference on December 2 deserves a spot on the calendar for owners of NYSE:SPGI. This is a company sitting in the middle...

Continue Reading
Lennar's 6.73% Slide Puts Disclosure Claims in Focus

Updated Category News Views 93

A homebuilder can survive ugly margins; murky demand signals are another beast entirely. Lennar is staring at a securities class action after a bruising run of disclosures and market reactions, and the central issue is not whether housing got tougher. Everybody with a pulse knew rates were squeezing buyers. The issue is whether NYSE:LEN gave investors a sufficiently clear...

Continue Reading
Cottage Grove Tests Holiday Demand Across Lake Norman

Updated Category News Views 120

Flour and foot traffic make a pretty honest little scoreboard. Cottage Grove Bakery is putting itself in front of Lake Norman shoppers twice on Saturday, November 21, while also taking Thanksgiving orders and laying groundwork for 2027 workplace and school visits. This is not a public-company earnings story, and nobody should pretend a tray of scones is a quarterly...

Continue Reading
Simmons Clarifies Texas Loan Exposure, But Risks Remain

Updated Category News Views 87

A $45 million discrepancy is not a rounding error, and Simmons First National has every reason to swat it down hard. The bank says recent reporting overstated financing tied to a Texas multifamily development at $133 million. Its stated total is roughly $88 million, with about $44 million participated to another financial institution. For shareholders in NASDAQ:SFNC, that...

Continue Reading
Allooloo's 100M Calls Test Capital Markets AI Data

Updated Category News Views 138

Forty-one point nine thousand issuers is a lot of financial clutter to keep straight, and Allooloo says its machines are getting called on to do precisely that at industrial scale. The Vancouver-based company reported on November 20 that its capital-markets data products now receive 100 million AI-agent calls a month—roughly 3.4 million daily, or 39 per second. That is...

Continue Reading
PexarBolt's CES Honor Meets a Real Crowdfunding Test

Updated Category News Views 52

A little touchscreen bolted onto a dock would usually make me roll my eyes. This time, Pexar has at least put enough muscle behind the gimmick to deserve a harder look. The PexarBolt Ultra TBT5 Dock was named a CES Innovation Awards 2027 Honoree in Computer Peripherals & Accessories, following an IFA 2026 Innovation Awards honor only two months after its launch. Awards do...

Continue Reading
Surf City Seasons Put Vacation Rental Timing in Focus

Updated Category News Views 42

Summer’s Calendar Does the Talking School bells, not seagulls, appear to set the pace for Surf City’s rental market. Chris Rackley’s seasonal guide makes a pretty grounded point: the “best” time to visit Surf City, North Carolina, is not some universal magic week on a postcard. It depends on whether a traveler needs peak beach weather, wants elbow room, or...

Continue Reading
Dallas College Recognition Signals Workforce Value

Updated Category News Views 63

Economic mobility rarely arrives with brass bands, but it can show up in a community-college ranking. Dallas College has landed on TIME and Statista's inaugural America’s Best Community Colleges 2027 list, one of 250 schools selected from roughly 1,100 nationwide. For a region that keeps talking about talent pipelines, this is a useful piece of outside validation—not...

Continue Reading

Top 5 Most Recently Viewed Articles

Hyundai Unveils Palisade with John Krasinski for Epic Campaign

Updated Category News Views 223

Hyundai Launches 'Make Everyday Epic' Campaign Hyundai is thrilled to announce its latest marketing strategy highlighted by the Palisade Hybrid SUV, a vehicle designed to enrich everyday experiences. With its stunning aesthetics and performance capabilities, the Palisade emerges as a perfect choice for those seeking a touch of luxury in their daily activities. Epic...

Continue Reading
Olympus Corporation Updates Landscape with New CPT Codes

Updated Category News Views 238

Olympus Corporation Introduces New CPT Codes for ESD Olympus Corporation, a pioneering global medical technology company, has taken a significant step towards enhancing patient care in the realm of gastrointestinal health. Recently, the American Medical Association (AMA) announced the establishment of new Category I CPT codes for the Endoscopic Submucosal Dissection (ESD)...

Continue Reading
Audience Town's Conversion-Focused Tool Transforms Home Building

Updated Category News Views 156

Introducing Audience Town's New Tool for Home Builders Audience Town, a pioneering platform in home building performance analytics, has recently launched the Audience Targeting Add-On. This innovative tool marks a significant milestone for builders, providing them with the ability to retarget their highest-value website visitors effectively, effectively eliminating...

Continue Reading
Investor Class Action Alerts: Navigating Recent Legal Developments

Updated Category News Views 182

Investor Class Action Alerts: An Overview In today's marketplace, investors remain vigilant against various legal risks as class action lawsuits emerge against publicly traded companies. These lawsuits can significantly affect shareholders who are often left navigating complex legal landscapes. A recent reminder from The Law Offices of Frank R. Cruz regarding upcoming...

Continue Reading
Elisity’s Texas Water Pilot Puts IonQ’s Deal in View

Updated Category News Views 261

Water-system security is not a place for chest-thumping Elisity’s role in Texas Project Watershed 250 lands on a problem that is painfully concrete: water and wastewater utilities have to keep pumps, treatment systems and plant operations running while trying to close cybersecurity gaps. That is a tougher job than selling another dashboard to a corporate IT department....

Continue Reading